HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Human epidermal growth factor receptor type 2 (HER2)-negative breast cancer is one of the most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can generally be subdivided into two major groups: HER2-, estrogen receptor (ER)+ and/or progesterone receptor (PR)+ and HER2-, ER-, and PR- (triple-negative breast cancer, or TNBC). Historically HR+ breast cancer has typically been treated with hormone therapies which is the cornerstone of treatment for patients with this disease while physicians have typically relied on chemotherapy for patients with triple negative breast cancer. This has significantly changed in the last 5 years.
GlobalData is expecting a total of 9 new entrants to launch over the forecast period in the 8MM from 2018–2028 while specific marketed agents are expected to move into earlier lines of treatment. The competition will be particularly fierce in HER2-/HR+ breast cancer, with CDK4/6, PI3K/AKT, and HDAC inhibitors competing for market share with endocrine-based therapies in later lines of treatment. In TNBC, checkpoint inhibitors, PARP inhibitors and antibody drug conjugates will compete in specific patient segments, and are expected to ultimately lower the unmet needs in this patient population.
KEY QUESTIONS ANSWERED
Nine late-stage pipeline agents are going to enter the HER2-negative breast cancer market from 2018 onwards. Will the impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
What are the current unmet needs in HER2-negative breast cancer, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
What is the market outlook in the 8MM from 2018-2028? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
What are the main corporate trends? Who are the current and future players?

Scope

Overview of HER2-negative breast cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline HER2-negative breast cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting HER2-negative breast cancer therapeutics sales in the 8MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).

Analysis of the current and future market competition in the global HER2-negative breast cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The main drivers of growth include the anticipated approval and launch of 9 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.

The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.

Among the late-stage pipeline products and marketed agents, CDK4/6 inhibitors, checkpoint inhibitors and PI3K/AKT inhibitors are expected to generate the greatest revenues over the forecast period.

The most important unmet needs in the HER2-negative market include: Personalized therapies in TNBC, agents to tackle endocrine resistance and improved convenience for administration of hormone therapies.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global HER2-negative breast cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2-negative breast cancer market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global HER2-negative breast cancer therapeutics market from 2018-2028.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Pfizer
Roche
Astrazeneca
Novartis
Eli Lilly
Merck
 Eisai
 Celgene
 Chipscreen biosciences
OBI Pharma
PolyPhor
Syndax
Radius Health
Immunomedics 

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 HER2-Negative Breast Cancer: Executive Summary

2.1 The HER2-Negative Breast Cancer Market Will Expand to $12.22B in 2028

2.2 A Focus on Establishing Greater Market Access, Label Expansions for Premium Products, and New Products in Later Lines

2.3 Opportunities Remain for More Effective and Conveniently Administered Therapies in HER2-Negative Breast Cancer

2.4 Checkpoint Inhibitors and PI3K/AKT Inhibitors Are Well Positioned for Significant Market Penetration Over the Forecast Period

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan

5.3.4 China (Urban)

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Sources Not Used – 5EU

5.4.3 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for HER2-Negative Breast Cancer (2018–2028)

5.5.1 Diagnosed Incident Cases of All Invasive Breast Cancer

5.5.2 Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer

5.5.3 Diagnosed Incident Cases of HER2-/HR+ Breast Cancer

5.5.4 Diagnosed Incident Cases of TN Breast Cancer

5.5.5 Proportion of Diagnosed Incident cases of HER2-/HR+ Breast Cancer by Stages

5.5.6 Proportion of Diagnosed Incident cases of TN Breast Cancer by Stages

5.5.7 Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Menopausal Status

5.5.8 Diagnosed Incident cases of HER2-Negative Breast Cancer by PD-1 and PD-L1 Expression

5.5.9 Diagnosed Incident Cases of HER2-Negative Breast Cancer with BRCA Mutation

5.5.10 Diagnosed Incident Cases of HER2-Negative Breast Cancer with PI3KCA Mutation

5.5.11 Diagnosed Incident Cases of HER2-Negative Breast Cancer by Bone Metastasis

5.5.12 Diagnosed Incident Cases of HER2-Negative Breast Cancer with Brain/CNS Metastasis

5.5.13 Five-Year Diagnosed Prevalent Cases of All Invasive Breast Cancer

5.5.14 Five-Year Diagnosed Prevalent Cases of HER2-Negative Breast cancer

5.5.15 10-Year Diagnosed Prevalent Cases of All Invasive Breast Cancer

5.5.16 10-Year Diagnosed Prevalent Cases of HER2-Negative Breast cancer

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

6.5 China

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Developing More Personalized Treatment Options for TNBC Patients

8.3 Developing Novel Strategies to Tackle Endocrine Resistance in HR+ Disease

8.4 Improved Convenience for Administration of Hormonal Agents

8.5 Effective Treatment Strategies for Patients with Brain Metastases

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Pfizer

10.4 Novartis

10.5 Eli Lilly

10.6 AstraZeneca

10.7 Roche

10.8 Merck & Co

10.9 Other Players

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – Key Opinion Leaders Interviewed for This Report

12.4.1 Key Opinion Leaders

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: HER2-Negative Breast Cancer Key Metrics in the 8MM

Table 2 : Inherited Gene Mutations Associated With Lifetime Breast Cancer Risk

Table 3: Established and Probable Risk Factors Associated With Breast Cancer Development

Table 4: Molecular Subtypes of Breast Cancer

Table 5: AJCC Stage Definitions for Breast Cancer

Table 6: Risk Factors and Comorbidities for All Invasive Breast Cancer

Table 7: Treatment Guidelines for HER-/HR+ Breast Cancer

Table 8: Country Profile – US

Table 9: Country Profile – 5EU

Table 10: Country Profile – Japan

Table 11: Country Profile – China

Table 12: Leading Treatments for HER2-Negative Breast Cancer

Table 13: Pfizer’s HER2-Negative Breast Cancer Portfolio Assessment, 2019

Table 14: Novartis’s Disease Portfolio Assessment, 2019

Table 15: Eli Lilly’s Disease Portfolio Assessment, 2019

Table 16: AstraZeneca’s Disease Portfolio Assessment, 2019

Table 17: Roche’s Disease Portfolio Assessment, 2019

Table 18: Merck’s Disease Portfolio Assessment, 2019

Table 19: Eisai’s, Celgene’s, R-Pharm’s, Radius Health’s, Immunomedics’, OBI Pharma’s, and Polphor’s Disease Portfolio Assessment, 2019

Table 20: HER2-Negative Breast Cancer Market – Global Drivers and Barriers, 2018–2028

Table 21: Key Events Impacting Sales for HER2-Negative Breast Cancer in the US, 2018–2028

Table 22: HER2-Negative Breast Cancer Market – Drivers and Barriers in the US, 2018–2028

Table 23: Key Events Impacting Sales for HER2-Negative Breast Cancer in the 5EU, 2018–2028

Table 24: HER2-Negative Breast Cancer Market – Drivers and Barriers in the 5EU, 2018–2028

Table 25: Key Events Impacting Sales for HER2-Negative Breast Cancer in Japan, 2018–2028

Table 26: HER2-Negative Breast Cancer Market – Drivers and Barriers in Japan, 2018–2028

Table 27: Key Events Impacting Sales for HER2-Negative Breast Cancer in China, 2018–2028

Table 28: HER2-Negative Breast Cancer Market – Global Drivers and Barriers in China, 2018–2028

Table 29: Key Historical and Projected Launch Dates for HER2-Negative Breast Cancer

Table 30: Key Historical and Projected Patent Expiry Dates for HER2-Negative Breast Cancer

Table 31: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for HER2-Negative Breast Cancer in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in HER2-Negative Breast Cancer During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of HER2-Negative Breast Cancer During the Forecast Period

Figure 4: 8MM, Diagnosed Incidence Rates of All Invasive Breast Cancer, Ages ≥18 Years, Women, Cases per 100,000 Population, 2008‒2028

Figure 5: Sources Used for Diagnosed Incident Cases of All Invasive Breast Cancer

Figure 6: Sources Used for Diagnosed Incident Cases of HER2-/HR+ and TN Breast Cancer

Figure 7 : Sources Used for Diagnosed Incident Cases of HER2-/HR+ and TN Breast Cancer by Stage

Figure 8: Sources Used for Diagnosed Prevalent Cases of All Invasive Breast Cancer

Figure 9 : Diagnosed Incident Cases of All Invasive Breast Cancer, 8MM, Women, Ages ≥18 Years, 2018

Figure 10: 8MM, Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer, Women, Ages ≥18 Years, N, 2018

Figure 11: Diagnosed Incident Cases of HER2-/HR+ Breast Cancer, 8MM, Women, Ages ≥18 Years, N, 2018

Figure 12: Diagnosed Incident Cases of TN Breast Cancer, 8MM, Women, Ages ≥18 Years, N, 2018

Figure 13: Proportion of Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Stage, 8MM, Women, Ages ≥18 Years, N, 2018

Figure 14: Proportion of Diagnosed Incident Cases of TN Breast Cancer by Stage, 8MM, Women, Ages ≥18 Years, 2018

Figure 15: Proportion of HER2-/HR+ Breast Cancer by Menopausal Status, 8MM, Women, Ages ≥18 Years, 2018

Figure 16: HER2-Negative Breast Cancer by PD-1 and PD-L1 Expression, 8MM, Women, Ages ≥18 Years, 2018

Figure 17: Diagnosed Incident Cases of HER2-Negative Breast Cancer with BRCA Mutation, 8MM, Women, Ages ≥18 Years, 2018

Figure 18: HER2-Negative Breast Cancer by PI3K and AKT Mutation, 8MM, Women, Ages ≥18 Years, 2018

Figure 19: Diagnosed Incident Cases of HER2-Negative Breast Cancer by Bone Metastasis, 8MM, Women, Ages ≥18 Years, 2018

Figure 20: Diagnosed Incident Cases of HER2-Negative Breast Cancer with Brain/CNS Metastasis, 8MM, Women, Ages ≥18 Years, 2018

Figure 21 : Five-Year Diagnosed Prevalent Cases of All Invasive Breast Cancer, 8MM, Women, Ages ≥18 Years, 2018

Figure 22 : Five-Year Diagnosed Prevalent Cases of HER2-Negative Breast Cancer, 8MM, Women, Ages ≥18 Years, N, 2018

Figure 23 : 10-Year Diagnosed Prevalent Cases of All Invasive Breast Cancer, 8MM, Women, Ages ≥18 Years, N, 2018

Figure 24 : 10-Year Diagnosed Prevalent Cases of HER2-Negative Breast Cancer, 8MM, Women, Ages ≥18 Years, N, 2018

Figure 25 : An Overview of the Treatment Algorithm in Non-invasive and Invasive Breast Cancer

Figure 26 : An overview of the neoadjuvant/adjuvant settings treatment paradigm

Figure 27 : An Overview of the Treatment Paradigm in the Metastatic HER2-Negative Setting

Figure 28: Unmet Needs and Opportunities in HER2-Negative Breast Cancer

Figure 29: Overview of the Development Pipeline in HER2-Negative Breast Cancer

Figure 30: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for HER2-Negative Breast Cancer in the 8MM During the Forecast Period

Figure 31: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of HER2-Negative Breast Cancer During the Forecast Period

Figure 32: Analysis of the Company Portfolio Gap in HER2-Negative Breast Cancer During the Forecast Period

Figure 33: Global (8MM) Sales Forecast by Country for HER2-Negative Breast Cancer in 2018 and 2028

Figure 34: Sales Forecast by Class for HER2-Negative Breast Cancer in the US in 2018 and 2028

Figure 35: Sales Forecast by Class for HER2-Negative Breast Cancer in the 5EU in 2018 and 2028

Figure 36: Sales Forecast by Class for HER2-Negative Breast Cancer in Japan in 2018 and 2028

Figure 37: Sales Forecast by Class for HER2-Negative Breast Cancer in China in 2018 and 2028

Frequently asked questions

HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2028 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2028 in real time.

  • Access a live HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.